Armata Pharmaceuticals, Inc. 宣布,计划将其候选药物AP-Sa02推进至针对复杂性金黄色葡萄球菌菌血症的3期优效性临床研究阶段。公司预计,该项关键研究将于2026年下半年正式启动。
Armata Pharmaceuticals, Inc. 宣布,计划将其候选药物AP-Sa02推进至针对复杂性金黄色葡萄球菌菌血症的3期优效性临床研究阶段。公司预计,该项关键研究将于2026年下半年正式启动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.